

**1. Number of SAS-B approvals for Category 1 CBD oral liquid (CBD  $\geq$ 98%)**

- **2021 (Nov – Dec):** 1,884
- **2022:** 19,792
- **2023:** 21,710
- **2024:** 29,165
- **2025 (Jan – May):** 12,880

*Note: Data is provided for the period 01/11/21 to 31/05/25. 'Oil' and 'Solution' are not captured as separate dosage forms and are encompassed by 'Oral Liquid' in SAS submission data. All approvals above are associated with an oral route of administration.*

**2. Number of Category 1 CBD products reported by sponsors (CBD  $\geq$ 98%)**

- **2021 (Jul – Dec):** 49
- **2022:** 97
- **2023:** 99
- **2024:** 142

*Note: Data is provided for the period 01/07/21 to 31/12/24. No data is available for 2025 as the relevant reporting period (1 Jan – 30 June 2025) has not yet closed. Data on route of administration is not gathered from sponsors. All relevant dosage forms have been included: 'Oral Liquid', 'Oil', 'Solution', 'Oral Oil', 'Oral Solution'.*

**3. Number of packs of Category 1 CBD products supplied under the SAS pathway as reported by sponsors (CBD  $\geq$ 98%)**

- **2021 (Jul – Dec):** 33,725
- **2022:** 45,600
- **2023:** 38,893
- **2024:** 57,093

*Note: Data is provided for the period 01/07/21 to 31/12/24. No data is available for 2025 as the relevant reporting period (1 Jan – 30 June 2025) has not yet closed. Data on route of administration is not gathered from sponsors. All relevant dosage forms have been included: 'Oral Liquid', 'Oil', 'Solution', 'Oral Oil', 'Oral Solution'.*